Ixinity Soon To Be Available in Larger Vial and Trial Likely in Younger Children with Hemophilia B, Aptevo Says
Aptevo Therapeutics provided an update on Ixinity, its hemophilia B therapy, that includes developing a larger 3,000 IU vial…
Articles by Iqra Mumal, MSc
FDA Approves Hemlibra to Treat Hemophilia A Without Factor VIII Inhibitors
The U.S. Food and Drug administration (FDA) has approved Genentech’s Hemlibra (emicizumab-kxwh) for routine prophylactic (preventive) treatment…
Phase 2/3 Clinical Trial of MarzAA Shows Promise in Hemophilia Treatment
Catalyst Biosciences announced positive interim results from a Phase 2/3 clinical trial (NCT03407651) of the Factor VIIa variant…
Multiple Factors Contribute to Development of FVIII Inhibitors in Hemophilia, Review Finds
Several genetic and environmental factors can play a role in the development of inhibitors against treatment with factor VIII in…
Employment Status, Pain, Low Physical Activity Linked to Anxiety, Depression in Hemophilia Patients
A study that examined the role of emotional distress in the lives of hemophilia patients found that a patient’s employment…
Gene Therapy Wins Over Prophylaxis in Cost-Benefit Analysis as Long-term Treatment for Severe Hemophilia A
A gene therapy that can treat patients with severe hemophilia A is likely to be more cost-effective over the long…
New Kit Demonstrates Clinical Validity as Measure of FVIII Inhibitors in Hemophilia A
Precision BioLogic revealed promising data on a new kit for the measurement of FVIII inhibitors (factor VIII) in patients…
XaTek Raises $9M to Advance ClotChip, Portable Device That Quickly Analyzes Blood’s Ability to Clot
XaTek announced that it has raised $9.1 million to advance the development of ClotChip — a portable test designed to…
Despite Protective Effects, Cardiovascular Disease Still a Risk in Moderate to Severe Hemophilia Patients, Study Finds
Although moderate to severe hemophilia patients are generally protected against the development of cardiovascular disease, cardiovascular-related events can still…
Canadian PREVAIL Trial Investigates Use of Wilate for Certain Hemophilia A Patients
Octapharma announced the launch of the PREVAIL clinical study (NCT03344003), which will investigate the use of Wilate…